Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Upadacitinib is a selective Janus kinase 1 inhibitor that was recently approved for treatment of rheumatoid arthritis and is currently being evaluated for treatment of several other autoimmune diseases, including atopic dermatitis (AD). The relationships between upadacitinib plasma exposure and effi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Pharmacol
Hlavní autoři: Mohamed, Mohamed‐Eslam F., Gopalakrishnan, Sathej, Teixeira, Henrique D., Othman, Ahmed A.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Exposure Response
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8049015/
https://ncbi.nlm.nih.gov/pubmed/33156550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1782
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky